Heart and liver diseases treatment specialist Sequana Medical has announced its alfapump has won the ‘Best Technology’ Award at the European Mediscience Awards in London.
The European Mediscience Awards event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. Bringing together the best of European mediscience companies to celebrate achievement and recognise success, its awards are hotly contested.
Ian Crosbie, CEO of Sequana Medical, commented: “We developed the alfapump to transform the lives of patients with recurrent or refractory ascites due to liver cirrhosis – a rapidly growing patient population due to NASH / NAFLD epidemic. Our objective is to replace the standard of care that has changed little in over 2,000 years and deliver improved clinical outcomes, quality of life and cost savings. The recognition of this work by our industry peers is a tremendous accolade for the Sequana team and celebrates all the hard work that has gone into developing this transformational device.”
About the alfapump
Sequana Medical’s alfapump is a fully implantable, wirelessly charged device which continuously collects ascites as it forms in the abdominal cavity and moves it into the bladder, where it is naturally passed from the body through urination.
In Europe, the alfapump has received CE mark-approval for the treatment of refractory ascites due to liver cirrhosis and malignant ascites and has been included in key European treatment guidelines. In the US, the Company’s key growth market, the alfapump has been granted breakthrough device designation by the Food and Drug Administration (FDA) for the treatment of recurrent or refractory ascites due to liver cirrhosis.
Our objective is to replace the standard of care that has changed little in over 2,000 years and deliver improved clinical outcomes, quality of life and cost savings
- Ian Crosbie, CEO of Sequana Medical
The POSEIDON study, intended to support the approval of the alfapump in North America, reported strong top-line results meeting all primary efficacy endpoints with statistical significance and safety in line with expectations. Filing of the pre-market approval (PMA) application with the US FDA is planned for H2 2023. Sequana Medical plans to commercialise the alfapump directly in the US, using a specialised in-house sales force targeting 90 liver transplant centres (covering 95% of adult liver transplants).
